Detecting Intact Virus Using Exogenous Oligonucleotide Labels
- PMID: 35584293
- PMCID: PMC12236977
- DOI: 10.1021/acs.analchem.2c00835
Detecting Intact Virus Using Exogenous Oligonucleotide Labels
Abstract
The COVID-19 pandemic has revealed how an emerging pathogen can cause a sudden and dramatic increase in demand for viral testing. Testing pooled samples could meet this demand; however, the sensitivity of reverse transcription quantitative polymerase chain reaction (RT-qPCR), the gold standard, significantly decreases with an increasing number of samples pooled. Here, we introduce detection of intact virus by exogenous-nucleotide reaction (DIVER), a method that quantifies intact virus and is robust to sample dilution. As demonstrated using two models of severe acute respiratory syndrome coronavirus 2, DIVER first tags membraned particles with exogenous oligonucleotides, then captures the tagged particles on beads functionalized with a virus-specific capture agent (in this instance, angiotensin-converting enzyme 2), and finally quantifies the oligonucleotide tags using qPCR. Using spike-presenting liposomes and spike-pseudotyped lentivirus, we show that DIVER can detect 1 × 105 liposomes and 100 plaque-forming units of lentivirus and can successfully identify positive samples in pooling experiments. Overall, DIVER is well positioned for efficient sample pooling and clinical validation.
Conflict of interest statement
The authors declare the following competing financial interest(s): T.R.C., M.K, and L.L.S. have submitted a U.S. patent application (PCT/US20/62957) involving the method to detect via qPCR lipid bilayer nanoparticles labeled with cholesterol-modified oligonucleotides.
Figures




Update of
-
Toward Community Surveillance: Detecting Intact SARS-CoV-2 Using Exogeneous Oligonucleotide Labels.medRxiv [Preprint]. 2021 Mar 26:2021.03.23.21254201. doi: 10.1101/2021.03.23.21254201. medRxiv. 2021. Update in: Anal Chem. 2022 May 31;94(21):7619-7627. doi: 10.1021/acs.analchem.2c00835. PMID: 33791715 Free PMC article. Updated. Preprint.
Similar articles
-
Antibody tests for identification of current and past infection with SARS-CoV-2.Cochrane Database Syst Rev. 2022 Nov 17;11(11):CD013652. doi: 10.1002/14651858.CD013652.pub2. Cochrane Database Syst Rev. 2022. PMID: 36394900 Free PMC article.
-
Toward Community Surveillance: Detecting Intact SARS-CoV-2 Using Exogeneous Oligonucleotide Labels.medRxiv [Preprint]. 2021 Mar 26:2021.03.23.21254201. doi: 10.1101/2021.03.23.21254201. medRxiv. 2021. Update in: Anal Chem. 2022 May 31;94(21):7619-7627. doi: 10.1021/acs.analchem.2c00835. PMID: 33791715 Free PMC article. Updated. Preprint.
-
Rapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 infection.Cochrane Database Syst Rev. 2022 Jul 22;7(7):CD013705. doi: 10.1002/14651858.CD013705.pub3. Cochrane Database Syst Rev. 2022. PMID: 35866452 Free PMC article.
-
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3. Cochrane Database Syst Rev. 2022. PMID: 35593186 Free PMC article.
-
Measures implemented in the school setting to contain the COVID-19 pandemic.Cochrane Database Syst Rev. 2022 Jan 17;1(1):CD015029. doi: 10.1002/14651858.CD015029. Cochrane Database Syst Rev. 2022. Update in: Cochrane Database Syst Rev. 2024 May 2;5:CD015029. doi: 10.1002/14651858.CD015029.pub2. PMID: 35037252 Free PMC article. Updated.
References
-
- Ritchie H; Mathieu E; Rodés-Guirao L; Appel C; Giattino C; Ortiz-Ospina E; Hasell J; Macdonald B; Beltekian D; Roser M Coronavirus Pandemic (COVID-19). https://ourworldindata.org/covid-vaccinations (accessed Sept 01, 2021).
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials